<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Valvular heart disease induced by drugs</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Valvular heart disease induced by drugs</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Valvular heart disease induced by drugs</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Theo E Meyer, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Catherine M Otto, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 29, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Drug-induced valvular heart disease refers to morphological and functional abnormalities of valve leaflets secondary to exposure to various medications. Ergot derivatives (<a class="drug drug_general" data-topicid="9416" href="/d/drug information/9416.html" rel="external">ergotamine</a> and methysergide) were the first drugs linked to valvulopathy. Subsequently, other drugs, such as <a class="drug drug_general" data-topicid="128557" href="/d/drug information/128557.html" rel="external">fenfluramine</a>, pergolide, and <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a>, have been implicated in causing valvular abnormalities [<a href="#rid1">1</a>]. The use of 3,4-methylenedioxymethamphetamine (MDMA, also known as ecstasy) may also induce valve disease. The common pathogenetic link is increased serotonin activity, since many of the drugs and their metabolites are potent 5-hydroxytryptamine<sub>2B</sub> (5-HT<sub>2B</sub>) receptor agonists [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The echocardiographic and pathologic features of the valve disease seen in patients with drug-induced valvular disease are similar to those occurring in carcinoid heart valve disease [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/d/html/8135.html" rel="external">"Carcinoid heart disease"</a>.)</p><p>The link between these two conditions appears to be serotonin, a neurotransmitter that is elevated in serum and plasma of most patients with carcinoid heart valve disease [<a href="#rid4">4</a>]. As noted above, <a class="drug drug_general" data-topicid="128557" href="/d/drug information/128557.html" rel="external">fenfluramine</a> and dexfenfluramine augment serotonergic activity, while <a class="drug drug_general" data-topicid="9765" href="/d/drug information/9765.html" rel="external">phentermine</a> may contribute to the fenfluramine valvulopathy by interfering with the pulmonary clearance of serotonin.</p><p>Serotonin is also thought to play a role in the valve disease associated with ergot derivatives <a class="drug drug_general" data-topicid="9416" href="/d/drug information/9416.html" rel="external">ergotamine</a> [<a href="#rid5">5</a>], methysergide [<a href="#rid6">6</a>], and the dopamine agonists pergolide and <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> [<a href="#rid7">7-9</a>]. These drugs are structurally similar to serotonin and are thought to produce valve disease by stimulation of serotonin (5-HT 2B) receptors [<a href="#rid7">7,10,11</a>]. (See <a class="local">'Parkinson disease'</a> below.)</p><p>Although serotonin appears to play a central role in drug-induced valve disease, selective serotonin reuptake inhibitors (<a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a>, and <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a>), which are commonly used for the treatment of depression and other disorders, do not appear to be associated with valve disease [<a href="#rid12">12</a>] (see  <a class="medical medical_review" href="/d/html/1713.html" rel="external">"Serotonin-norepinephrine reuptake inhibitors: Pharmacology, administration, and side effects"</a>). This may be because activation of serotonin-2B receptors, which are located on both mitral and aortic valves, is required to induce valve disease. Support for this hypothesis comes from a study that found that drugs associated with valvular heart disease or metabolites of such drugs, including <a class="drug drug_general" data-topicid="9416" href="/d/drug information/9416.html" rel="external">ergotamine</a> and metabolites of <a class="drug drug_general" data-topicid="128557" href="/d/drug information/128557.html" rel="external">fenfluramine</a>, dexfenfluramine, and methysergide, had high affinity for and were partial to full agonists of the serotonin-2B receptor [<a href="#rid10">10</a>]. By contrast, drugs not associated with valvular disease had low affinity for this receptor (<a class="drug drug_general" data-topicid="9765" href="/d/drug information/9765.html" rel="external">phentermine</a> and fluoxetine) or were a potent antagonist (<a class="drug drug_general" data-topicid="10013" href="/d/drug information/10013.html" rel="external">trazodone</a>).</p><p>Serotonin stimulates fibroblast growth and fibrogenesis, which appears to underlie the valve disease seen in patients with carcinoid and anorectic drug and ergot derivative related heart valve disease. More direct evidence for a central role of serotonin comes from studies in animals:</p><p class="bulletIndent1"><span class="glyph">●</span>In a rat model in which daily serotonin injections were given for three months, valvular abnormalities (aortic and/or pulmonary regurgitation) developed in six of ten rats, with histopathologic examination showed carcinoid-like plaques similar to those seen in humans with carcinoid heart disease [<a href="#rid13">13</a>]. There were no valvular changes in control rats.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another mechanism of raising serotonin levels is to interfere with its metabolism. This process is mediated in part by the 5-hydroxytryptamine (5-HT) transporter, which is responsible for serotonin inactivation as it passes through the lungs. Both valvular hyperplasia and fibrosis were observed in a mouse model in which the 5-HT transporter gene was knocked out [<a href="#rid14">14</a>].</p><p></p><p class="headingAnchor" id="H3549545567"><span class="h1">PREVENTION AND MANAGEMENT</span><span class="headingEndMark"> — </span>Initial recommendations from the Centers for Disease Control and Prevention, US Food and Drug Administration, and National Institutes of Health were issued in 1997 for patients who were exposed to <a class="drug drug_general" data-topicid="128557" href="/d/drug information/128557.html" rel="external">fenfluramine</a> or dexfenfluramine for any length of time [<a href="#rid15">15</a>]. More definitive recommendations were included in the 2003 American College of Cardiology/American Heart Association/American Society of Echocardiography guidelines on clinical application of echocardiography [<a href="#rid16">16</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Drugs linked to valvular heart disease such as <a class="drug drug_general" data-topicid="128557" href="/d/drug information/128557.html" rel="external">fenfluramine</a> and dexfenfluramine should be avoided. Caution is advised regarding the use of nonprescription anorectic drugs, herbal anorectics, and even diet supplements. The use of some ergot derivatives has also been shown to be associated with a valvulopathy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A cardiac history and physical examination, emphasizing cardiac auscultation, is indicated in all exposed patients. In the absence of abnormal findings, a repeat history and physical examination can be performed in six to eight months. The validity of this approach was illustrated in a study of 223 patients receiving dexfenfluramine for seven months; the absence of heart murmurs predicted the absence of echocardiographic valvular regurgitation in 93 percent of patients, while the presence of a murmur had a positive predictive value of only 19 percent [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Echocardiography to assess valve morphology and regurgitation is indicated in patients with a history of use of any drug associated with valvular heart disease who have a heart murmur, symptoms of valvular heart disease, or a technically inadequate auscultatory examination.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The optimal timing of follow-up echocardiography to determine the progression, regression, or stabilization of valvular lesions is not known. Routine repetition of echocardiography was not recommended in past users of anorectic drugs with normal studies or known trivial valvular abnormalities</p><p></p><p class="headingAnchor" id="H3"><span class="h1">ANORECTIC DRUGS</span><span class="headingEndMark"> — </span>The consequences of obesity include a variety of adverse health outcomes as well as social stigma [<a href="#rid18">18</a>] (see  <a class="medical medical_review" href="/d/html/5370.html" rel="external">"Overweight and obesity in adults: Health consequences"</a>). As a result, aggressive strategies have been developed for weight reduction in individuals with obesity. One such strategy is the prescription of appetite suppressing or anorectic drugs, usually in combination with diet, exercise, and behavior modification. Some of these drugs have been implicated in the pathogenesis of a characteristic form of valvular heart disease [<a href="#rid19">19,20</a>].</p><p>Patients who developed valve disease have generally been treated with an off-label <a class="drug drug_general" data-topicid="128557" href="/d/drug information/128557.html" rel="external">fenfluramine</a> in combination with <a class="drug drug_general" data-topicid="9765" href="/d/drug information/9765.html" rel="external">phentermine</a> (called "fen-phen"). (See  <a class="medical medical_review" href="/d/html/5376.html" rel="external">"Obesity in adults: Drug therapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Fenfluramine – <a class="drug drug_general" data-topicid="128557" href="/d/drug information/128557.html" rel="external">Fenfluramine</a> (Pondimin) is a sympathomimetic amine that promotes the release of serotonin and blocks its neuronal uptake. The ensuing increase in serotonergic activity has an anorectic effect. Fenfluramine was originally approved by the US Food and Drug Administration (FDA) in 1973 for single-drug, short term use as an appetite suppressant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dexfenfluramine – Dexfenfluramine (Redux) is the dextro isomer of <a class="drug drug_general" data-topicid="128557" href="/d/drug information/128557.html" rel="external">fenfluramine</a>. Its activity is relatively selective to serotonergic pathways in the brain, but the appetite suppression is similar to that of fenfluramine. In 1996, the FDA approved dexfenfluramine as a single-drug appetite suppressant for longer term use in individuals with marked obesity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Benflourex is an amphetamine derivative related to <a class="drug drug_general" data-topicid="128557" href="/d/drug information/128557.html" rel="external">fenfluramine</a> and dexfenfluramine. This agent was withdrawn from the European markets in 2010 following several reports linking this agent to three-fold increase in hospitalization for valve regurgitation [<a href="#rid21">21-23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Phentermine – <a class="drug drug_general" data-topicid="9765" href="/d/drug information/9765.html" rel="external">Phentermine</a> (Adipex, Fastin, Ionamin) is a noradrenergic central nervous system stimulant that was approved by the FDA as an appetite suppressant in 1959. When given alone, this agent has <strong>not</strong> been implicated in the pathogenesis of valvular heart disease.</p><p></p><p>Combinations of <a class="drug drug_general" data-topicid="128557" href="/d/drug information/128557.html" rel="external">fenfluramine</a> and <a class="drug drug_general" data-topicid="9765" href="/d/drug information/9765.html" rel="external">phentermine</a> (called fen/phen) have been used with the hope that weight reduction might be achieved with lower doses and fewer side effects (see  <a class="medical medical_review" href="/d/html/5376.html" rel="external">"Obesity in adults: Drug therapy"</a>). Most of the reported cases of valvular disease in patients taking anorectic drugs were in patients using this combination [<a href="#rid19">19,20</a>].</p><p>Approximately 18 million prescriptions were written for either <a class="drug drug_general" data-topicid="128557" href="/d/drug information/128557.html" rel="external">fenfluramine</a> or <a class="drug drug_general" data-topicid="9765" href="/d/drug information/9765.html" rel="external">phentermine</a> in 1996 [<a href="#rid24">24</a>]. In 1997 the FDA asked the manufacturers to withdraw fenfluramine and dexfenfluramine (but not phentermine) from the market. Assuming that the average prescription was written for one month and that the treatment course lasted three to twelve months, it is likely that several million Americans were exposed to these drugs.</p><p class="headingAnchor" id="H4"><span class="h2">Relation to valvular disease</span><span class="headingEndMark"> — </span>In 1997, cardiac ultrasonographers at the MeritCare Medical Center in Fargo, North Dakota and clinicians at the Mayo Clinic in Rochester, Minnesota described valvular heart disease in 24 women (average age 44) who had been treated with the combination of <a class="drug drug_general" data-topicid="128557" href="/d/drug information/128557.html" rel="external">fenfluramine</a> and <a class="drug drug_general" data-topicid="9765" href="/d/drug information/9765.html" rel="external">phentermine</a> [<a href="#rid19">19</a>]. All 24 had cardiac symptoms and/or a heart murmur. Aortic or mitral regurgitation (or both) was present in all 24; one-half also had tricuspid involvement. The average dose of fenfluramine was 60 mg/day and the dose of phentermine was 30 mg/day. The mean duration of treatment with fenfluramine-phentermine was 11 months (range 1 to 28 months). Five patients required valve replacement, while less severe valvular regurgitation was present in the remaining patients. (See  <a class="medical medical_review" href="/d/html/1078.html" rel="external">"Auscultation of cardiac murmurs in adults"</a>.)</p><p>An additional 28 cases were reported simultaneously by physicians from the FDA [<a href="#rid20">20</a>]. These patients, all women, exhibited a similar history of valvular heart disease in association with the use of a combination of <a class="drug drug_general" data-topicid="128557" href="/d/drug information/128557.html" rel="external">fenfluramine</a> and <a class="drug drug_general" data-topicid="9765" href="/d/drug information/9765.html" rel="external">phentermine</a>. As a result of these observations, the manufacturer withdrew fenfluramine and dexfenfluramine from the market (September 1997).</p><p>Subsequently, more than 100 additional provider-initiated case reports were received by the FDA. Valvulopathy was associated with the use of <a class="drug drug_general" data-topicid="128557" href="/d/drug information/128557.html" rel="external">fenfluramine</a> or dexfenfluramine, alone or in combination with <a class="drug drug_general" data-topicid="9765" href="/d/drug information/9765.html" rel="external">phentermine</a>. There were no cases with the use of phentermine alone.</p><p>Unfortunately, these initial descriptions of an association between valvulopathy and anorectic drugs do not represent epidemiologic or even case-control studies. Subsequent randomized and case-controlled studies provided additional information [<a href="#rid25">25-27</a>], but several issues remain unclear:</p><p class="bulletIndent1"><span class="glyph">●</span>The prevalence of regurgitant valvular lesions in patients with obesity not exposed to these drugs is not well-established. The patients in these reports did not routinely have echocardiography prior to drug therapy and it is therefore unclear how many may have had preexistent valvular abnormalities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The relative risks of <a class="drug drug_general" data-topicid="128557" href="/d/drug information/128557.html" rel="external">fenfluramine</a> and dexfenfluramine, alone or in combination with <a class="drug drug_general" data-topicid="9765" href="/d/drug information/9765.html" rel="external">phentermine</a>, as well as the effects of dose and duration of exposure are not well defined.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk factors for valvulopathy have not been defined. Baseline body weight, concomitant medications, and other demographic factors must be assessed.</p><p></p><p>A nonrandomized study compared the echocardiographic findings of 257 patients using any anorectic drugs with 239 control patients [<a href="#rid26">26</a>]. Mild or greater aortic regurgitation or moderate or greater mitral regurgitation were present in 1.3 percent of controls, 12.8 percent of patients receiving dexfenfluramine (odds ratio 12.7), 22.8 percent of those taking the combination of dexfenfluramine and <a class="drug drug_general" data-topicid="9765" href="/d/drug information/9765.html" rel="external">phentermine</a> (odds ratio 24.5), and 25.2 percent of patients taking both <a class="drug drug_general" data-topicid="128557" href="/d/drug information/128557.html" rel="external">fenfluramine</a> and phentermine (odds ratio 26.3)  (<a class="graphic graphic_figure graphicRef76203" href="/d/graphic/76203.html" rel="external">figure 1</a>).</p><p>A much lower prevalence of valvulopathy has been reported by others. One nonrandomized study examined 223 patients exposed to dexfenfluramine for a mean of 6.9 months and 189 unexposed controls; at least mild aortic regurgitation or moderate mitral regurgitation was significantly more frequent in patients treated with dexfenfluramine (7.6 versus 2.1 percent for controls) [<a href="#rid28">28</a>]. The difference was primarily due to more frequent mild aortic regurgitation (6.3 versus 1.6 percent)  (<a class="graphic graphic_figure graphicRef57538" href="/d/graphic/57538.html" rel="external">figure 2</a>). Factors independently associated with any grade of aortic regurgitation were older age, diastolic blood pressure greater than 95 mmHg  (<a class="graphic graphic_figure graphicRef67953" href="/d/graphic/67953.html" rel="external">figure 3</a>), and a shorter time from drug discontinuation to echocardiogram, which suggests that dexfenfluramine-related valve regurgitation may regress after drug discontinuation.</p><p>Another nonrandomized, but reader-blinded, controlled echocardiographic study of 934 patients treated for at least 30 days with dexfenfluramine or <a class="drug drug_general" data-topicid="9765" href="/d/drug information/9765.html" rel="external">phentermine</a>/<a class="drug drug_general" data-topicid="128557" href="/d/drug information/128557.html" rel="external">fenfluramine</a> and 539 untreated matched controls found an increase in the prevalence of aortic regurgitation with these drugs (8.9 and 13.7 versus 4.1 percent for placebo) but no difference in the prevalence of mitral regurgitation [<a href="#rid29">29</a>]. There was no difference in the rate of serious cardiac events (myocardial infarction, heart failure, or ventricular arrhythmia) in treated and untreated subjects.</p><p>In a prospective randomized trial of dexfenfluramine or sustained-release dexfenfluramine versus placebo administered for an average of 71 days, echocardiograms were obtained in 1072 patients within one month of treatment discontinuation [<a href="#rid25">25</a>]. There was a nonsignificant trend towards more valvular regurgitation with dexfenfluramine compared with placebo (6.5 and 7.3 versus 4.5 percent, respectively). The low incidence of valvulopathy in this report may have been due to the brief duration of therapy; the course of the valvular disease in these patients is discussed below. (See <a class="local">'Course'</a> below.)</p><p>Support for a relationship between the duration of therapy and the incidence of valvular abnormalities comes from the Boston Collaborative Drug Surveillance Program which conducted a population-based and a nested case-control analysis of 6532 subjects treated with dexfenfluramine, 2371 who received <a class="drug drug_general" data-topicid="128557" href="/d/drug information/128557.html" rel="external">fenfluramine</a>, 862 treated with <a class="drug drug_general" data-topicid="9765" href="/d/drug information/9765.html" rel="external">phentermine</a>, and 9281 individuals with obesity who did not take these drugs [<a href="#rid27">27</a>]. The five year cumulative incidence of an idiopathic valvular disorder was:</p><p class="bulletIndent1"><span class="glyph">●</span>0 per 10,000 among subjects who had not taken appetite suppressants or those who had taken <a class="drug drug_general" data-topicid="9765" href="/d/drug information/9765.html" rel="external">phentermine</a> alone</p><p class="bulletIndent1"><span class="glyph">●</span>7.1 per 10,000 among those treated with <a class="drug drug_general" data-topicid="128557" href="/d/drug information/128557.html" rel="external">fenfluramine</a> or dexfenfluramine for less than four months</p><p class="bulletIndent1"><span class="glyph">●</span>35 per 10,000 among patients treated with <a class="drug drug_general" data-topicid="128557" href="/d/drug information/128557.html" rel="external">fenfluramine</a> or dexfenfluramine for four or more months</p><p></p><p>Another report of 226 individuals with obesity followed prospectively for up to 30 months found significant, but not severe, aortic regurgitation in 6.6 percent and mitral regurgitation in 1.3 percent; there was no association with the dose administered or duration of therapy [<a href="#rid30">30</a>]. The prevalence of valvular regurgitation in this study was comparable to what has been found in the general population in the Framingham Heart Study [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H5"><span class="h3">Pathology</span><span class="headingEndMark"> — </span>The gross pathologic features included thickening of the mitral leaflets and chordae, with a glistening white appearance. The histopathologic picture is one of intact leaflet architecture with a plaque-like encasement of the leaflets; proliferative myofibroblasts are surrounded by an abundant extracellular matrix [<a href="#rid32">32</a>].</p><p>When cardiac valves excised from patients treated with anorexic agents were compared with normal and rheumatic valves, distinctive histopathologic features were identified [<a href="#rid33">33</a>]. For example, valves exposed to anorexic drugs showed a larger number of onlays (plaques) per valve, while rheumatic valves showed the greatest average onlay size and thickness. The valve onlays from anorexic agent-exposed valves contained a higher percentage of glycosaminoglycans compared with normal and rheumatic valves.</p><p class="headingAnchor" id="H6"><span class="h2">Echocardiography</span><span class="headingEndMark"> — </span>The 2003 guidelines from the American College of Cardiology, the American Heart Association, and the American Society of Echocardiography (ACC/AHA/ASE) recommended echocardiography to assess valve morphology and regurgitation in patients with a history of use of anorectic drugs or any other drug known to be associated with valvular heart disease, particularly those who are symptomatic, have cardiac murmurs, or have a technically inadequate auscultatory examination [<a href="#rid16">16</a>]. Routine screening of all patients who have taken anorectic drugs was not recommended.</p><p>The echocardiographic features of the valvulopathy are similar to those seen in some patients with rheumatic heart disease, but valve obstruction is conspicuously absent. The most common mitral valve findings include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Thickening and diastolic doming of the anterior mitral leaflets with relative immobility of the posterior leaflets</p><p class="bulletIndent1"><span class="glyph">●</span>Prominent subvalvular disease with thickening and shortening of the chordae tendineae</p><p class="bulletIndent1"><span class="glyph">●</span>Leaflet tethering and malcoaptation contribute to the mitral regurgitation</p><p></p><p>The aortic valves appear thickened with leaflet retraction, although aortic regurgitation can occur in the presence of echocardiographically normal leaflets.</p><p class="headingAnchor" id="H7"><span class="h3">FDA case definition</span><span class="headingEndMark"> — </span>Minor degrees of regurgitation (trace or mild mitral regurgitation or trace aortic regurgitation) are relatively common in the general population and may occur without valvular disease [<a href="#rid34">34</a>]. Therefore, these lesser degrees of regurgitation were excluded from the 1997 FDA case definition of <a class="drug drug_general" data-topicid="128557" href="/d/drug information/128557.html" rel="external">fenfluramine</a> or dexfenfluramine-associated valvulopathy. The FDA case definition requires documented mild or greater aortic regurgitation OR moderate or greater mitral regurgitation [<a href="#rid15">15</a>].</p><p>Although not included in the FDA case definition, rates of significant (greater than mild) tricuspid regurgitation may approach those for significant mitral regurgitation [<a href="#rid35">35,36</a>]. Tricuspid leaflets may be thickened with restricted mobility.</p><p class="headingAnchor" id="H8"><span class="h2">Course</span><span class="headingEndMark"> — </span>Echocardiography has been used to evaluate the course of valvular heart disease associated with anorectic drugs. The valvular lesions tend to be stable or improve in the great majority of patients after the cessation of these drugs [<a href="#rid37">37-40</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>One of the trials described above randomly assigned over 1000 patients to dexfenfluramine, sustained-release dexfenfluramine, or placebo for an average of only 71 days [<a href="#rid25">25</a>]. Echocardiograms were obtained one month and one year after discontinuation in 914 patients [<a href="#rid37">37</a>]. The major finding was greater regression of aortic regurgitation compared with the placebo group but no change in mitral regurgitation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar findings were noted in a second report of 50 patients with previous exposure to fenfluramines who had at least mild mitral (76 percent) and/or aortic regurgitation (86 percent) [<a href="#rid39">39</a>]. An initial echocardiogram was obtained a mean of 190 days after drug cessation and repeat echocardiography performed approximately one year later. Among the 38 patients with mitral regurgitation, 17 improved, 19 experienced no change, and 2 worsened by at least one grade. Among the 43 patients with aortic regurgitation, 19 improved, 22 were stable, and two worsened by at least one grade.</p><p></p><p class="headingAnchor" id="H9"><span class="h1">ERGOT DERIVATIVES</span><span class="headingEndMark"> — </span>Valve disease has resulted from use of ergot derivatives in the treatment of migraine and, less commonly, in the treatment of hyperprolactinemia. Ergot derivatives are no longer used to treat Parkinson disease given the risk of valve disease.</p><p class="headingAnchor" id="H10"><span class="h2">Migraine</span><span class="headingEndMark"> — </span>The ergot derivatives <a class="drug drug_general" data-topicid="9416" href="/d/drug information/9416.html" rel="external">ergotamine</a> and methysergide have limited utility for treatment and prophylaxis of migraines largely due to their adverse effects which include induction of valvular disease [<a href="#rid5">5,6,41-45</a>]. Although most reported cases of valve disease have been asymptomatic, some patients have developed symptoms and required valve replacement. (See  <a class="medical medical_review" href="/d/html/3347.html" rel="external">"Acute treatment of migraine in adults"</a> and  <a class="medical medical_review" href="/d/html/3345.html" rel="external">"Preventive treatment of episodic migraine in adults"</a>.)</p><p class="headingAnchor" id="H2488042334"><span class="h2">Hyperprolactinemia</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">Cabergoline</a> associated valvular disease has only rarely been reported in patients treated for hyperprolactinemia. In the United Kingdom study cited above, for example, only one of the 31 patients with valve disease were being treated for hyperprolactinemia compared with 29 for Parkinson disease [<a href="#rid8">8</a>]. This difference is at least in part dose-dependent. As noted above, the risk of valve disease is particularly increased at doses higher than 3 mg/day [<a href="#rid8">8</a>]; in comparison, the recommended cabergoline dose for hyperprolactinemia is only 0.5 to 2 mg per week. (See  <a class="medical medical_review" href="/d/html/6630.html" rel="external">"Management of hyperprolactinemia", section on 'Overview of dopamine agonists'</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Parkinson disease</span><span class="headingEndMark"> — </span>Ergot-derived dopamine agonists pergolide and <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> were previously used to treat Parkinson disease and were associated with a clinically significant risk of valvular heart disease, with lesions similar to those associated with carcinoid, fenfluramine-induced, and other ergot-induced valvular disease [<a href="#rid7">7-9,46-50</a>]. The risk of valvular disease appears to increase relative to the cumulative dose of pergolide or cabergoline. As with anorectic drugs, the mechanism is probably related to pergolide and cabergoline activation of serotonin (5-HT 2B type) receptors expressed on heart valves, which in turn leads to valvular overgrowth [<a href="#rid11">11</a>]. (See <a class="local">'Pathogenesis'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>In a nested case-control study from the United Kingdom involving a cohort of 11,417 patients taking antiparkinsonian drugs, 31 patients with newly diagnosed cardiac valve regurgitation were compared with 664 controls; six were taking pergolide and six were taking <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> [<a href="#rid8">8</a>]. The risk of cardiac valve regurgitation was significantly increased with current use of pergolide (incidence-rate ratio [IRR] 7.1, 95% CI 2.3-22.3) and cabergoline (IRR 4.9, 95% CI 1.5-15.6) but not with other dopamine agonists. The risk of cardiac valve regurgitation was increased only for patients taking pergolide or cabergoline for six months or longer, and was particularly increased for both medications at doses higher than 3 mg daily.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a case-control study from Italy involving 155 patients taking dopamine agonists for Parkinson disease and 90 control subjects, the frequency of clinically important valve regurgitation determined by echocardiography was significantly higher in patients taking pergolide or <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> compared with controls (23.4 and 28.6 versus 5.6 percent, respectively) but not in those taking nonergot dopamine agonists (0 percent) [<a href="#rid9">9</a>].</p><p></p><p>Thus, pergolide and <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> should <strong>NOT</strong> be used as treatment for Parkinson disease. In the United States, pergolide was voluntarily withdrawn from the market in March 2007 due to the potential risk of heart valve damage [<a href="#rid51">51</a>]. </p><p class="headingAnchor" id="H13"><span class="h1">MDMA (ECSTASY)</span><span class="headingEndMark"> — </span>Limited data suggest that use of 3,4-Methylenedioxymethamphetamine (MDMA; known as ecstasy) may cause valve disease. An in vitro study found that MDMA and its N-demethylated metabolite 3,4-methylenedioxyamphetamine activated the 5-hydroxytryptamine 2B (5-HT2B) serotonin receptor and elicited a prolonged mitogenic response in human valvular interstitial cells similar to that induced by <a class="drug drug_general" data-topicid="128557" href="/d/drug information/128557.html" rel="external">fenfluramine</a> [<a href="#rid52">52</a>].</p><p>A preliminary report of 29 current or former users of MDMA and 29 sex- and age-matched controls found that 8 of 29 MDMA users had abnormal echocardiographic results (using the FDA case definition for valvulopathy due to appetite suppressant drugs [<a href="#rid15">15</a>] (see <a class="local">'FDA case definition'</a> above)), compared with none in the control group [<a href="#rid53">53</a>]. Among MDMA users, 13 had greater than mild tricuspid regurgitation and six had valvular strands; neither of these findings was present in any of the control subjects.</p><p>Other cardiovascular effects of MDMA are discussed separately. (See  <a class="medical medical_review" href="/d/html/302.html" rel="external">"MDMA (ecstasy) intoxication"</a>.)</p><p class="headingAnchor" id="H2968149100"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115482.html" rel="external">"Society guideline links: Cardiac valve disease"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Drugs linked to valvular heart disease such as <a class="drug drug_general" data-topicid="128557" href="/d/drug information/128557.html" rel="external">fenfluramine</a> and dexfenfluramine should be avoided. Caution is advised regarding the use of nonprescription anorectic drugs, herbal anorectics, and even diet supplements. The use of some ergot derivatives has also been shown to be associated with a valvulopathy. (See <a class="local">'Prevention and management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A cardiac history and physical examination, emphasizing cardiac auscultation, is indicated in all patients exposed to drugs associated with valvular heart disease. (See <a class="local">'Prevention and management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Echocardiography to assess valve morphology and regurgitation is indicated in patients with a history of use of any drug associated with valvular heart disease who have a heart murmur, symptoms of valvular heart disease, or a technically inadequate auscultatory examination. (See <a class="local">'Prevention and management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The optimal timing of follow-up echocardiography to determine the progression, regression, or stabilization of valvular lesions is not known. Routine repetition of echocardiography was not recommended in past users of anorectic drugs with normal studies or known trivial valvular abnormalities. (See <a class="local">'Prevention and management'</a> above.)</p><p></p><p class="headingAnchor" id="H4206269219"><span class="h1">ACKNOWLEDGMENTS</span></p><p>The UpToDate editorial staff acknowledges William H Gaasch, MD (deceased), who contributed to an earlier version of this topic review.</p><p>The UpToDate editorial staff acknowledges Gerard P Aurigemma, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bhattacharyya S, Schapira AH, Mikhailidis DP, Davar J. Drug-induced fibrotic valvular heart disease. Lancet 2009; 374:577.</a></li><li><a class="nounderline abstract_t">Huang XP, Setola V, Yadav PN, et al. Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment. Mol Pharmacol 2009; 76:710.</a></li><li><a class="nounderline abstract_t">Pellikka PA, Tajik AJ, Khandheria BK, et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation 1993; 87:1188.</a></li><li><a class="nounderline abstract_t">Robiolio PA, Rigolin VH, Wilson JS, et al. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 1995; 92:790.</a></li><li><a class="nounderline abstract_t">Hendrikx M, Van Dorpe J, Flameng W, Daenen W. Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature. J Heart Valve Dis 1996; 5:235.</a></li><li><a class="nounderline abstract_t">Bana DS, MacNeal PS, LeCompte PM, et al. Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. Am Heart J 1974; 88:640.</a></li><li><a class="nounderline abstract_t">Waller EA, Kaplan J, Heckman MG. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2005; 80:1016.</a></li><li><a class="nounderline abstract_t">Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007; 356:29.</a></li><li><a class="nounderline abstract_t">Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007; 356:39.</a></li><li><a class="nounderline abstract_t">Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000; 102:2836.</a></li><li><a class="nounderline abstract_t">Roth BL. Drugs and valvular heart disease. N Engl J Med 2007; 356:6.</a></li><li><a class="nounderline abstract_t">Mast ST, Gersing KR, Anstrom KJ, et al. Association between selective serotonin-reuptake inhibitor therapy and heart valve regurgitation. Am J Cardiol 2001; 87:989.</a></li><li><a class="nounderline abstract_t">Gustafsson BI, Tømmerås K, Nordrum I, et al. Long-term serotonin administration induces heart valve disease in rats. Circulation 2005; 111:1517.</a></li><li><a class="nounderline abstract_t">Mekontso-Dessap A, Brouri F, Pascal O, et al. Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation 2006; 113:81.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb Mortal Wkly Rep 1997; 46:1061.</a></li><li class="breakAll">Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline for the clinical application of echocardiography www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).</li><li><a class="nounderline abstract_t">Roldan CA, Gill EA, Shively BK. Prevalence and diagnostic value of precordial murmurs for valvular regurgitation in obese patients treated with dexfenfluramine. Am J Cardiol 2000; 86:535.</a></li><li><a class="nounderline abstract_t">Rosenbaum M, Leibel RL, Hirsch J. Obesity. N Engl J Med 1997; 337:396.</a></li><li><a class="nounderline abstract_t">Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337:581.</a></li><li><a class="nounderline abstract_t">Graham DJ, Green L. Further cases of valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337:635.</a></li><li><a class="nounderline abstract_t">Weill A, Païta M, Tuppin P, et al. Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus. Pharmacoepidemiol Drug Saf 2010; 19:1256.</a></li><li><a class="nounderline abstract_t">Tribouilloy C, Maréchaux S, Jobic Y, et al. Frequency of drug-induced valvular heart disease in patients previously exposd to benfluorex: a multicentre prospective study. Eur Heart J 2013; 34:3580.</a></li><li><a class="nounderline abstract_t">Tribouilloy C, Rusinaru D, Andréjak M. How can benfluorex-related heart valve disease be identified by echocardiography? Arch Cardiovasc Dis 2011; 104:489.</a></li><li class="breakAll">Langreth R. Critics claim diet clinics misuse obesity drugs. Wall Street Journal. March 31, 1997;B8.</li><li><a class="nounderline abstract_t">Weissman NJ, Tighe JF Jr, Gottdiener JS, Gwynne JT. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. N Engl J Med 1998; 339:725.</a></li><li><a class="nounderline abstract_t">Khan MA, Herzog CA, St Peter JV, et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med 1998; 339:713.</a></li><li><a class="nounderline abstract_t">Jick H, Vasilakis C, Weinrauch LA, et al. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 1998; 339:719.</a></li><li><a class="nounderline abstract_t">Shively BK, Roldan CA, Gill EA, et al. Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. Circulation 1999; 100:2161.</a></li><li><a class="nounderline abstract_t">Gardin JM, Schumacher D, Constantine G, et al. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000; 283:1703.</a></li><li><a class="nounderline abstract_t">Burger AJ, Sherman HB, Charlamb MJ, et al. Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months. J Am Coll Cardiol 1999; 34:1153.</a></li><li><a class="nounderline abstract_t">Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 1999; 83:897.</a></li><li><a class="nounderline abstract_t">Caccitolo JA, Connolly HM, Rubenson DS, et al. Operation for anorexigen-associated valvular heart disease. J Thorac Cardiovasc Surg 2001; 122:656.</a></li><li><a class="nounderline abstract_t">McDonald PC, Wilson JE, Gao M, et al. Quantitative analysis of human heart valves: does anorexigen exposure produce a distinctive morphological lesion? Cardiovasc Pathol 2002; 11:251.</a></li><li><a class="nounderline abstract_t">Klein AL, Burstow DJ, Tajik AJ, et al. Age-related prevalence of valvular regurgitation in normal subjects: a comprehensive color flow examination of 118 volunteers. J Am Soc Echocardiogr 1990; 3:54.</a></li><li><a class="nounderline abstract_t">Teramae CY, Connolly HM, Grogan M, Miller FA Jr. Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience. Mayo Clin Proc 2000; 75:456.</a></li><li><a class="nounderline abstract_t">Dahl CF, Allen MR, Urie PM, Hopkins PN. Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals. BMC Med 2008; 6:34.</a></li><li><a class="nounderline abstract_t">Weissman NJ, Panza JA, Tighe JF, Gwynne JT. Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 134:267.</a></li><li><a class="nounderline abstract_t">Gardin JM, Weissman NJ, Leung C, et al. Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine. JAMA 2001; 286:2011.</a></li><li><a class="nounderline abstract_t">Mast ST, Jollis JG, Ryan T, et al. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography. Ann Intern Med 2001; 134:261.</a></li><li><a class="nounderline abstract_t">Klein AL, Griffin BP, Grimm RA, et al. Natural history of valvular regurgitation using side-by-side echocardiographic analysis in anorexigen-treated subjects. Am J Cardiol 2005; 96:1711.</a></li><li><a class="nounderline abstract_t">Graham JR. Cardiac and pulmonary fibrosis during methysergide therapy for headache. Am J Med Sci 1967; 254:1.</a></li><li><a class="nounderline abstract_t">Misch KA. Development of heart valve lesions during methysergide therapy. Br Med J 1974; 2:365.</a></li><li><a class="nounderline abstract_t">Redfield MM, Nicholson WJ, Edwards WD, Tajik AJ. Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med 1992; 117:50.</a></li><li><a class="nounderline abstract_t">Wilke A, Hesse H, Hufnagel G, Maisch B. Mitral, aortic and tricuspid valvular heart disease associated with ergotamine therapy for migraine. Eur Heart J 1997; 18:701.</a></li><li><a class="nounderline abstract_t">Martínez Quintana E, Llorens León R, Redondo Martínez E, et al. [Valvular heart disease associated with ergotamine]. Rev Esp Cardiol 2005; 58:97.</a></li><li><a class="nounderline abstract_t">Flowers CM, Racoosin JA, Lu SL, Beitz JG. The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 2003; 78:730.</a></li><li><a class="nounderline abstract_t">Pritchett AM, Morrison JF, Edwards WD, et al. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2002; 77:1280.</a></li><li><a class="nounderline abstract_t">Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363:1179.</a></li><li><a class="nounderline abstract_t">Baseman DG, O'Suilleabhain PE, Reimold SC, et al. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 2004; 63:301.</a></li><li><a class="nounderline abstract_t">Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007; 6:826.</a></li><li class="breakAll">US Food and Drug Administration. FDA announces voluntary withdrawal of pergolide products (March 29, 2007). http://www.fda.gov/newsevents/newsroom/pressannouncements/2007/ucm108877.htm (Accessed on August 01, 2012).</li><li><a class="nounderline abstract_t">Setola V, Hufeisen SJ, Grande-Allen KJ, et al. 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 2003; 63:1223.</a></li><li><a class="nounderline abstract_t">Droogmans S, Cosyns B, D'haenen H, et al. Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. Am J Cardiol 2007; 100:1442.</a></li></ol></div><div id="topicVersionRevision">Topic 8125 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19683643" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Drug-induced fibrotic valvular heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19570945" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7681733" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7641358" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8665020" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4420941" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cardiac murmurs and endocardial fibrosis associated with methysergide therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16092580" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Valvular heart disease in patients taking pergolide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17202453" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Dopamine agonists and the risk of cardiac-valve regurgitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17202454" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Valvular heart disease and the use of dopamine agonists for Parkinson's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11104741" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17202450" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Drugs and valvular heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11305992" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Association between selective serotonin-reuptake inhibitor therapy and heart valve regurgitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15781732" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Long-term serotonin administration induces heart valve disease in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16380550" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9385873" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9385873" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11009272" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prevalence and diagnostic value of precordial murmurs for valvular regurgitation in obese patients treated with dexfenfluramine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9241130" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9271479" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Valvular heart disease associated with fenfluramine-phentermine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9280830" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Further cases of valvular heart disease associated with fenfluramine-phentermine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20945504" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24014218" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Frequency of drug-induced valvular heart disease in patients previously exposd to benfluorex: a multicentre prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22044700" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : How can benfluorex-related heart valve disease be identified by echocardiography?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22044700" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : How can benfluorex-related heart valve disease be identified by echocardiography?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9731088" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9731086" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9731087" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10571975" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10755496" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10520805" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10190406" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11581595" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Operation for anorexigen-associated valvular heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12361835" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Quantitative analysis of human heart valves: does anorexigen exposure produce a distinctive morphological lesion?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2310593" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Age-related prevalence of valvular regurgitation in normal subjects: a comprehensive color flow examination of 118 volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10807073" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18990200" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11182836" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy. A randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11667938" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11182835" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The progression of fenfluramine-associated valvular heart disease assessed by echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16360362" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Natural history of valvular regurgitation using side-by-side echocardiographic analysis in anorexigen-treated subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6027684" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cardiac and pulmonary fibrosis during methysergide therapy for headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4835843" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Development of heart valve lesions during methysergide therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1596047" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9129909" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Mitral, aortic and tricuspid valvular heart disease associated with ergotamine therapy for migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15680136" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : [Valvular heart disease associated with ergotamine].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12934784" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12479512" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Valvular heart disease in patients taking pergolide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15081648" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15277624" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Pergolide use in Parkinson disease is associated with cardiac valve regurgitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17706566" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17706566" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12761331" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17950805" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
